Description
Chlorodehydromethyltestosterone (Turinabol, T-Bol, Oral Turinabol) is a synthetic testosterone derivative synthesized in East Germany by Jenapharm for doping research in state sports programs. Structurally Turinabol is a chlorinated methyltestosterone derivative - the additional chloro modification at C4 and the 1,2-double bond substantially alter the pharmacology profile.
Per study reports Turinabol binds to the androgen receptor with moderate affinity. The substance doesn’t aromatize to estradiol - the chlorinated structure blocks aromatase. This yields a classical “dry” profile without water retention and without estrogen-mediated effects.
The central property that made Turinabol popular in East German sports research: moderate anabolic action with low androgenic activity and low HPG axis suppression compared to Dianabol. This made Turinabol the perfect “stealth” compound for state doping programs between 1968 and 1989.
Pharmacokinetically orally bioavailable with about 16-hour half-life. Once- to twice-daily doses suffice. Like all 17α-methyl steroids Turinabol is hepatotoxic but milder than Dianabol or Stanozolol in available data.
Known effects in studies: moderate ALT/AST elevation, unfavorable lipid profile, mild HPG suppression, long-lived doping metabolites (Turinabol metabolites were detected in 2012 in the re-test of the 2008 Olympics, years after the competitions).
You can order Turinabol as oral tablets in one bottle with 25mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Chlorodehydromethyltestosterone is considered milder in hepatotoxicity than Dianabol or Stanozolol in available data, yet as a 17α-methyl steroid it still sits clearly in the upper range of the risk scale. The effects documented in the literature affect the liver, lipid profile and hormonal balance.
Documented in studies and the user literature:
- Liver strain: as a 17α-methyl steroid, Turinabol is hepatotoxic. Moderate ALT/AST elevations are documented, milder than under Dianabol or Stanozolol, but present.
- Lipid profile: studies describe an unfavorable lipid profile without an estrogen-mediated counter-effect, since Turinabol does not aromatize.
- Suppression of natural production: HPG suppression is documented in the literature, milder than under Dianabol, but established.
- Long-lived metabolites: a very long detectability of the metabolites is documented, found in re-tests years after use.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government - Clinical Chemistry 1997, Franke et al: Historical analysis of the state East German doping program with Oral Turinabol.
- Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine - Journal of Steroid Biochemistry and Molecular Biology 2012, Sobolevsky et al: Identification of long-term metabolites enabling re-tests years after use.
- Controlled administration of dehydrochloromethyltestosterone in humans: Urinary excretion and long-term detection of metabolites for anti-doping purpose - Journal of Steroid Biochemistry and Molecular Biology 2021, Loke et al: Controlled human administration study on pharmacokinetics and detectability.
- Cardiotoxicity of anabolic steroids; animal case study of oral turinabol and methanabol - Toxicology Letters 2014, Tsitsimpikou et al: Animal study on cardiotoxic effects of Oral Turinabol.
- Intratesticular leiomyosarcoma in a young man after high dose doping with oral-turinabol - Cancer 1999, Froehner et al: Case report on rare testicular tumor after high-dose doping.
